Technical Analysis for BYSI - BeyondSpring, Inc.

Grade Last Price % Change Price Change
F 1.71 -0.58% -0.01
BYSI closed down 0.58 percent on Wednesday, November 20, 2024, on 65 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Boomer Sell Setup Bearish Swing Setup -0.58%
Calm After Storm Range Contraction -0.58%
NR7 Range Contraction -0.58%
Lower Bollinger Band Walk Weakness -0.58%
Inside Day Range Contraction -0.58%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 21 hours ago
Down 2 % about 21 hours ago
Down 1% about 21 hours ago
Possible NR7 1 day ago
Possible Inside Day 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BeyondSpring, Inc. Description

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatment Chemotherapy Antineoplastic Drugs Small Cell Lung Cancer Cancer Therapies Organic Chemistry NSCLC Protein Kinase Advanced Non Small Cell Lung Cancer Buparlisib Docetaxel Neutropenia

Is BYSI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Nov 11 BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
Sep 16 BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC
Sep 16 BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
Sep 16 BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
Sep 10 BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Me...
Sep 3 BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
Aug 31 Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth?
Aug 6 SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
Jun 12 BeyondSpring files to offer up to 10M ordinary shares
May 22 BeyondSpring (NASDAQ:BYSI) shareholders have earned a 141% return over the last year
See more BYSI news...

Indicators

Indicator Value
52 Week High 4.0
52 Week Low 0.7777
Average Volume 24,409
200-Day Moving Average 2.24
50-Day Moving Average 2.17
20-Day Moving Average 1.99
10-Day Moving Average 1.80
Average True Range 0.17
RSI (14) 32.43
ADX 33.58
+DI 7.21
-DI 23.90
Chandelier Exit (Long, 3 ATRs) 1.84
Chandelier Exit (Short, 3 ATRs) 2.01
Upper Bollinger Bands 2.41
Lower Bollinger Band 1.57
Percent B (%b) 0.17
BandWidth 42.07
MACD Line -0.15
MACD Signal Line -0.11
MACD Histogram -0.0323
Fundamentals Value
Market Cap 66.72 Million
Num Shares 39 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -2.41
Price-to-Sales 35.99
Price-to-Book 5.38
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.82
Resistance 3 (R3) 1.81 1.77 1.80
Resistance 2 (R2) 1.77 1.75 1.78 1.79
Resistance 1 (R1) 1.74 1.73 1.72 1.75 1.79
Pivot Point 1.70 1.70 1.69 1.71 1.70
Support 1 (S1) 1.67 1.68 1.65 1.68 1.63
Support 2 (S2) 1.63 1.66 1.64 1.63
Support 3 (S3) 1.60 1.63 1.62
Support 4 (S4) 1.61